HomeSample Page

Sample Page Title



A four-drug chemotherapy routine supplied longer total survival than a two-drug mixture in a Section 3 medical trial for metastatic pancreatic ductal adenocarcinoma. The examine is believed to be the primary metastatic pancreatic most cancers examine in practically a decade to have a constructive endpoint for total survival.

Dr. Zev Wainberg, co-director of the UCLA Well being GI Oncology Program and a researcher at UCLA Jonsson Complete Most cancers Heart, is first writer of the oral summary describing the outcomes introduced on the ASCO Gastrointestinal Cancers Symposium Jan. 20 in San Francisco.

There have been a number of chemotherapy regimens used to deal with newly recognized, metastatic pancreas most cancers, additionally known as stage 4, however there have been few head-to-head comparisons to see which routine would produce an extended total survival. These trials assist reply critically vital therapy questions for all who deal with pancreas most cancers.”


Dr. Zev Wainberg, Co-Director of the UCLA Well being GI Oncology Program

For the examine, 770 sufferers have been randomly assigned to considered one of two chemotherapy regimens. Sufferers within the four-drug group had an total survival of 11.1 months, in contrast with 9.2 months for these within the two-drug arm. Development-free survival additionally elevated with the four-drug remedy – 7.4 months versus 5.6 months with the two-drug routine. A number of unwanted side effects, similar to diarrhea, nausea and low ranges of potassium, have been extra widespread in sufferers taking the four-drug therapy, however anemia and low ranges of white blood cells have been extra widespread in these taking the 2 medication.

The four-drug routine consisted of liposomal irinotecan, 5-fluorouracil/leucovorin and oxaliplatin – collectively known as NALIRIFOX. The 2-drug remedy consisted of nab-paclitaxel and gemcitabine.

“This examine signifies that the extra aggressive chemotherapy strategy ought to be thought-about for these sufferers who’re in a position to tolerate it,” Wainberg mentioned. “Metastatic pancreas most cancers has lengthy been acknowledged as a really tough kind of most cancers to deal with, however this examine represents a attainable new reference normal for present therapy and for future analysis and drug improvement.”

The medical trial included sufferers in additional than 25 international locations, with Dr. Eileen O’Reilly, a GI most cancers specialist at Memorial Sloan Kettering Most cancers Heart, serving as senior investigator.

ASCO, the American Society of Medical Oncology, will maintain the Gastrointestinal Cancers Symposium Jan. 19-21 on-line and at Moscone West in San Francisco.

RELATED ARTICLES

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Most Popular

Recent Comments